enVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

- Achieved more than half of enrollment in U.S. SAVVE pivotal trial of VenoValve® in 2022- Multiple near-term milestones expected across VenoValve® and enVVe clinical programs- Ended the year with $39.1

Related Keywords

California ,United States ,Colombia ,Irvine ,Dennis Riedl ,Jenene Thomas ,Robert Berman ,Exchange Commission ,Vveno Medical Corporation The Company ,Vveno Medical Corporation ,Clinical Program ,Medical Corporation ,Surgical Replacement Venous ,Surgical Anti Reflux Venous Valve Endoprosthesis ,Transcatheter Anti Reflux ,Venous Valve Endoprosthesis ,Financial Results ,Full Year ,Chronic Venous Insufficiency ,Private Securities Litigation Reform Act ,Medical Corporationview ,Envveno ,Medical ,Corporation ,Reports ,Fourth ,Quarter ,Ear ,022 ,Financial ,Results ,Rovides ,Corporate ,Update ,